New Cigna/ESI Insulin Savings Program Introduced Ahead of Congressional Hearing
Cigna and Express Scripts announced a new insulin “Patient Assurance Program” that will cap the out-of-pocket cost for a 30-day insulin supply to $25 for eligible patients on participating plans (Cigna purchased ESI in December 2018). Of note, the new savings program was announced ~1 week ahead of the third Senate Finance Committee hearing on drug pricing which is scheduled for April 9, 2019, at 10:15 AM ET. The third installment, titled “Drug Pricing in America: A Prescription for Change, Part III,” will focus specifically on the role of PBMs. Below, FENIX provides thoughts on the Cigna/ESI insulin savings program as an obvious strategy to redirect the focus away from themselves and back onto insulin manufacturers.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.